Form 4: Stoke Therapeutics CEO Edward M. Kaye Acquires Stock Options and Restricted Stock Units
SEC Form 4
CEO Edward M. Kaye of Stoke Therapeutics, Inc. reports acquisition of stock options and restricted stock units.
Summary
- On March 27, 2024, Edward M. Kaye, CEO of Stoke Therapeutics, acquired 159,000 employee stock options with an exercise price of $14.17.
- These options vest monthly starting April 15, 2024, over a four-year period, contingent upon continued service.
- Kaye also acquired 105,000 restricted stock units (RSUs) on the same date.
- These RSUs vest annually beginning March 15, 2025, also contingent upon continued service.
- Each RSU represents the right to receive one share of Stoke Therapeutics' common stock upon settlement.
- The options expire on March 26, 2034.
- The reporting person's attorney-in-fact, Jonathan Allan, signed the form on June 7, 2024.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, aligning management interests with shareholders. The vesting schedules suggest a long-term commitment from the CEO.
Positives
- The acquisition of stock options and RSUs by the CEO aligns his interests with those of the shareholders, incentivizing him to improve company performance.
- The vesting schedules for both the options and RSUs encourage long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules suggest a continued commitment from the CEO for the next four years.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates the CEO's continued investment in the company's future.
Comparison to Industry Standards
- Stock option and RSU grants are common forms of executive compensation in the biotechnology industry.
- Vesting schedules are typically structured to incentivize long-term performance and retention, similar to practices at companies like Vertex Pharmaceuticals and Biogen.
Stakeholder Impact
- Shareholders may view the CEO's acquisition of stock options and RSUs positively, as it aligns his interests with theirs.
- Employees may see this as a sign of the CEO's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction: CEO acquired stock options and RSUs. |
| 04/15/2024 | First vesting date for the stock options (1/48 of the total award). |
| 03/15/2025 | First annual vesting date for the RSUs (1/4 of the total award). |
| 03/26/2034 | Expiration date for the stock options. |
| 06/07/2024 | Date the Form 4 was signed by the attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.